Literature DB >> 27357007

Megakaryocytes regulate the quiescence of hematopoietic stem cells through PF4: 2013 ASH meeting highlights.

Yamei Chen1, Delong Liu1.   

Abstract

Hematopoietic stem cells (HSCs) can take one of the three different pathways: quiescence, self-renewal and differentiation. Mechanisms that control the tight balance to maintain lifelong hematopoietic homeostasis have been a major interest of research. Platelet factor-4 (PF4), a weak chemokine, is synthesized exclusively by megakaryocytes and sequestered in platelets. This meeting report highlights a novel study presented at 2013 ASH annual meeting. This study found that megakaryocyte, a progeny of HSC, was involved in maintaining quiescence of HSCs via PF4 in a feedback loop.

Entities:  

Keywords:  Hematopoietic stem cell (HSC); megakaryocytes; platelet factor-4 (PF4)

Year:  2014        PMID: 27357007      PMCID: PMC4923518          DOI: 10.3978/j.issn.2306-9759.2014.03.05

Source DB:  PubMed          Journal:  Stem Cell Investig        ISSN: 2306-9759


  14 in total

1.  A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration.

Authors:  Thorsten Buch; Frank L Heppner; Christine Tertilt; Tobias J A J Heinen; Marcel Kremer; F Thomas Wunderlich; Steffen Jung; Ari Waisman
Journal:  Nat Methods       Date:  2005-06       Impact factor: 28.547

2.  A 13-24 C-terminal peptide related to PF4 accelerates hematopoietic recovery of progenitor cells in vivo in mice treated with 5-fluorouracil.

Authors:  S Aïdoudi; I Lebeurier; J Amiral; G Quentin; J P Caen; Z C Han
Journal:  Int J Hematol       Date:  1997-12       Impact factor: 2.490

3.  New insights into the negative regulation of hematopoiesis by chemokine platelet factor 4 and related peptides.

Authors:  L Lecomte-Raclet; M Alemany; A Sequira-Le Grand; J Amiral; G Quentin; A M Vissac; J P Caen; Z C Han
Journal:  Blood       Date:  1998-04-15       Impact factor: 22.113

4.  A novel role for factor VIII and thrombin/PAR1 in regulating hematopoiesis and its interplay with the bone structure.

Authors:  Anna Aronovich; Yaniv Nur; Elias Shezen; Chava Rosen; Yael Zlotnikov Klionsky; Irit Milman; Liran Yarimi; David Hagin; Gidi Rechavi; Uriel Martinowitz; Takashi Nagasawa; Paul S Frenette; Dalit Tchorsh-Yutsis; Yair Reisner
Journal:  Blood       Date:  2013-08-27       Impact factor: 22.113

5.  In vivo effect of platelet factor 4 (PF4) and tetrapeptide AcSDKP on haemopoiesis of mice treated with 5-fluorouracil.

Authors:  S Aidoudi; M Guigon; I Lebeurier; J P Caen; Z C Han
Journal:  Br J Haematol       Date:  1996-09       Impact factor: 6.998

6.  Platelet factor-4 inhibits the mitogenic activity of VEGF121 and VEGF165 using several concurrent mechanisms.

Authors:  S Gengrinovitch; S M Greenberg; T Cohen; H Gitay-Goren; P Rockwell; T E Maione; B Z Levi; G Neufeld
Journal:  J Biol Chem       Date:  1995-06-23       Impact factor: 5.157

Review 7.  Clinical applications of mesenchymal stem cells.

Authors:  Shihua Wang; Xuebin Qu; Robert Chunhua Zhao
Journal:  J Hematol Oncol       Date:  2012-04-30       Impact factor: 17.388

Review 8.  Role of platelet chemokines, PF-4 and CTAP-III, in cancer biology.

Authors:  Katerina Pilatova; Kristina Greplova; Regina Demlova; Beatrix Bencsikova; Giannoula Lakka Klement; Lenka Zdrazilova-Dubska
Journal:  J Hematol Oncol       Date:  2013-06-24       Impact factor: 17.388

9.  Expansion of hematopoietic stem cells for transplantation: current perspectives.

Authors:  Jessica A Schuster; Maria R Stupnikov; Gina Ma; Wenbin Liao; Raymond Lai; Yupo Ma; Jerell R Aguila
Journal:  Exp Hematol Oncol       Date:  2012-05-14

10.  CD133: a stem cell biomarker and beyond.

Authors:  Zhong Li
Journal:  Exp Hematol Oncol       Date:  2013-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.